Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 113
Filter
1.
Drug Deliv ; 24(1): 608-621, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28240046

ABSTRACT

More than 35 million people are living with HIV worldwide with approximately 2.3 million new infections per year. Cascade of events (cell entry, virus replication, assembly and release of newly formed virions) is involved in the HIV-1 transmission process. Every single step offers a potential therapeutic strategy to halt this progression and HIV fusion into the human host cell is one such stage. Controlling the initial event of HIV-1 transmission is the best way to control its dissemination especially when prophylaxis is concerned. Action is required either on the HIV's or host's cell surface which is logically more rational when compared with other intracellular acting moieties. Aim of this manuscript is to detail the significance and current strategies to halt this initial step, thus blocking the entry of HIV-1 for further infection. Both HIV-1 and the possible host cell's receptors/co-receptors are under focus while specifying the targets available for inhibiting this fusion. Current and under investigation moieties are categorized based on their versatile mechanisms. Advanced drug delivery and nanotechnology approaches present a key tool to exploit the therapeutic potential in a boosted way. Current drug delivery and the impact of nanotechnology in potentiating this strategy are detailed.


Subject(s)
Anti-HIV Agents/therapeutic use , Drug Delivery Systems/methods , HIV Infections/drug therapy , HIV-1/drug effects , Nanomedicine/methods , Virus Attachment/drug effects , Virus Internalization/drug effects , Animals , Anti-HIV Agents/adverse effects , Drug Carriers , Drug Compounding , Drug Discovery/methods , HIV Fusion Inhibitors/therapeutic use , HIV Infections/metabolism , HIV Infections/transmission , HIV Infections/virology , HIV-1/metabolism , HIV-1/pathogenicity , Host-Pathogen Interactions , Humans , Molecular Targeted Therapy , Nanoparticles , Pre-Exposure Prophylaxis , Technology, Pharmaceutical/methods
2.
Pharm Dev Technol ; 21(8): 951-960, 2016 Dec.
Article in English | MEDLINE | ID: mdl-26334961

ABSTRACT

Currently, one-third of the world's population is infected with tuberculosis (TB) mainly spread by inhalation of the tubercle bacilli, Mycobacterium tuberculosis. Patient non-compliance is the major reason for failure of anti-tubercular drugs (ATDs) chemotherapy due to multidrug administration for longer duration of time period. The main aim of current research study was to develop and characterize inhalable spray-dried particles for pulmonary delivery of ATDs, i.e., rifampicin (RIF) and isoniazid (INH). ATDs-loaded alginate particles were prepared by ionotropic gelation technique followed by spray drying and characterized on the basis of various evaluation parameters. Results showed that the optimized spray-dried particles were found to be spherical in shape with excellent flow properties. The drug release showed the biphasic pattern of release, i.e., initial burst (30-40% up to 4 h) followed by a sustained release pattern (90% up to 60 h). Optimized formulations exhibited lower cytotoxicity and excellent lung uptake up to 8 h. Optimized formulation also showed higher rate and extent of drug uptake by lungs due to preferential phagocytosis be macrophage. In future, alginate particles could be a promising carrier for targeted delivery of ATDs to alveolar macrophages for efficient management of TB.


Subject(s)
Antitubercular Agents/administration & dosage , Antitubercular Agents/chemistry , Lung/metabolism , Tuberculosis/drug therapy , Administration, Inhalation , Alginates/chemistry , Animals , Chemistry, Pharmaceutical/methods , Delayed-Action Preparations/administration & dosage , Drug Compounding/methods , Drug Delivery Systems/methods , Female , Glucuronic Acid/chemistry , Hexuronic Acids/chemistry , Isoniazid/administration & dosage , Isoniazid/chemistry , Mice , Mice, Inbred BALB C , Mycobacterium tuberculosis/drug effects , Particle Size , Rifampin/administration & dosage , Rifampin/chemistry
3.
Drug Deliv ; 23(6): 1912-25, 2016 Jul.
Article in English | MEDLINE | ID: mdl-25544602

ABSTRACT

In the present study, nanostructured lipid carriers (NLCs) along with various surfactants loaded with paclitaxel (PTX) were prepared by an emulsification technique using a Box-Behnken design. The Box-Behnken design indicated that the most effective factors on the size and PDI were at high surfactant concentration (1.5%), low lipids ratio (6:4) and medium homogenization speed (6000 rpm). Among all the formulations, Tween 20-loaded NLCs show least particle size compared to Tween 80 and Tween 60. Entrapment efficiency of Tween 20, Tween 80 and Tween 60-loaded formulations were 82.40, 85.60 and 79.78%, respectively. Drug release of Tween 80, Tween 20 and Tween 60-loaded NLCs is 64.9, 62.3 and 59.7%, respectively (within 72 h). Maximum cellular uptake was observed with Tween 20 formulation on Caco-2 cell lines. Furthermore, spray drying of resultant NLCs was showed good flow properties and was selected for drug delivery to deeper airways. In-vivo studies demonstrated the better localization of drug within the lungs using different surfactant-based pulmonary delivery systems. From this study, we have concluded that delivering drugs through pulmonary route is advantageous for local action in lungs as maximum amount of drug concentration was observed in lungs. The surfactants could prove to be beneficial in treating drug resistance lung cancer by inhibiting P-gp efflux in the form of nano lipidic carriers.


Subject(s)
Drug Carriers , Drug Resistance, Neoplasm/drug effects , Lipids/chemistry , Lung Neoplasms/chemistry , Nanoparticles/chemistry , Nanostructures/chemistry , Paclitaxel/administration & dosage , Pulmonary Surfactants/chemistry , Caco-2 Cells , Chemistry, Pharmaceutical , Drug Delivery Systems , Humans , Lung Neoplasms/metabolism , Paclitaxel/chemistry , Paclitaxel/pharmacokinetics
4.
Drug Deliv ; 23(1): 123-9, 2016.
Article in English | MEDLINE | ID: mdl-24786480

ABSTRACT

CONTEXT: Artemether and lumefantrine combination therapy is well-accepted for uncomplicated malaria treatment. However, the current available formulation has several pharmacokinetic mismatches such as drug degradation in gastrointestinal tract, erratic absorption, etc. Hence, need of the hour is the injectable formulation, which can overcome the pharmacokinetic mismatch associated with current available formulation in the market. OBJECTIVE: To fabricate artemether and lumefantrine co-loaded injectable nanostructured lipid carriers (NLCs) formulation. MATERIALS AND METHODS: Artemether and lumefantrine co-loaded NLCs were fabricated using homogenization followed by ultra-sonication method. Fabricated NLCs were evalauated for their physicochemical characteristics, and suitability of the formulation for malaria treatment was evaluated using in vivo animal model (Plasmodium berghei-infected mice). Results, discussion and conclusion: Artemether and lumefantrine co-loaded NLCs had a hydrodynamic diameter of ∼ 145 nm with the surface charge of -66 mV. Due to the lipophilic nature of both antimalarial drugs, both single drugs-loaded and co-loaded NLCs have shown high encapsulation efficiency, which is 84% for artemether and 79% for lumefantrine. In vitro drug release study has shown a biphasic drug release pattern, which has shown 63% artemether release and 45% of lumefantrine release over a time period of 30 h. Plasmodium berghei-infected mice treated with artemether and lumefantrine co-loaded NLCs showed better antimalarial activity with respect to parasitemia progression and survivability period.


Subject(s)
Antimalarials/administration & dosage , Antimalarials/pharmacology , Artemisinins/administration & dosage , Artemisinins/pharmacology , Ethanolamines/administration & dosage , Ethanolamines/pharmacology , Fluorenes/administration & dosage , Fluorenes/pharmacology , Animals , Artemether , Drug Carriers , Lipids/chemistry , Lumefantrine , Malaria/drug therapy , Malaria/parasitology , Mice , Nanostructures , Particle Size , Plasmodium berghei
5.
Drug Deliv ; 23(3): 727-38, 2016.
Article in English | MEDLINE | ID: mdl-25013959

ABSTRACT

Among all cancers, lung cancer is the major cause of deaths. Lung cancer can be categorized into two classes for prognostic and treatment purposes: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Both categories of cancer are resistant to certain drugs. Various mechanisms behind drug resistance are over-expression of superficial membrane proteins [glycoprotein (P-gp)], lung resistance-associated proteins, aberration of the intracellular enzyme system, enhancement of the cell repair system and deregulation of cell apoptosis. Structure-performance relationships and chemical compatibility are consequently major fundamentals in surfactant-based formulations, with the intention that a great deal investigation is committed to this region. With the purpose to understand the potential of P-gp in transportation of anti-tumor drugs to cancer cells with much effectiveness and specificity, several surfactant-based delivery systems have been developed which may include microspheres, nanosized drug carriers (nanoparticles, nanoemulsions, stealth liposomes, nanogels, polymer-drug conjugates), novel powders, hydrogels and mixed micellar systems intended for systemic and/or localized delivery.


Subject(s)
Antineoplastic Agents/administration & dosage , Antineoplastic Agents/chemistry , Drug Delivery Systems/methods , Drug Resistance, Neoplasm/drug effects , Lung Neoplasms/drug therapy , Surface-Active Agents/administration & dosage , Surface-Active Agents/chemistry , Animals , Humans
6.
Int J Pharm ; 485(1-2): 108-21, 2015 May 15.
Article in English | MEDLINE | ID: mdl-25735668

ABSTRACT

In the present study, nanostructured lipid carriers (NLCs) with three different lipid combinations (solid lipid:liquid lipid) were prepared through emulsification and ultrasonication using a Box-Behnken design. From the design, the best lipid combination was glyceryl monostearate and oleic acid, which gives particle of smaller size (223.73 ± 43.39nm) with high drug entrapment efficiency (78.65 ± 2.2%). In vitro release studies show that 84.60 ± 5.66% of drug was released in 24h. In vivo studies revealed that drug absorption occurs through lymphatic pathway as only 5.008 ± 0.011µg/ml of peak plasma concentration was achieved in blood plasma in presence of chylomicron inhibitor. The peak plasma concentration (Cmax) for silymarin loaded NLC was found to be 25.565 ± 0.969µg/ml as compared to silymarin suspension whose Cmax was found to be 14.050 ± 0.552 µg/ml, this confirms 2-fold increase in relative bioavailability. In vivo studies revealed that 19.268 ± 1.29µg of drug reaches to liver in 2h whereas negligible drug concentration reported in other organs. It was concluded that drug loaded NLCs was beneficial for targeting liver or other lymphatic disorders through lymphatic transport pathway. Finally, the main purpose of modifying lymphatic transport system was successfully achieved through NLCs.


Subject(s)
Drug Carriers , Glycerol/chemistry , Liver/metabolism , Lymphatic System/metabolism , Nanoparticles , Oleic Acid/chemistry , Silymarin/administration & dosage , Administration, Oral , Animals , Biological Availability , Caco-2 Cells , Chemistry, Pharmaceutical , Chylomicrons/metabolism , Emulsions , Female , Glycerol/analogs & derivatives , Humans , Hydrophobic and Hydrophilic Interactions , Intestinal Absorption , Metabolic Clearance Rate , Models, Statistical , Nanomedicine , Particle Size , Rats, Wistar , Silymarin/blood , Silymarin/chemistry , Silymarin/pharmacokinetics , Solubility , Sonication , Technology, Pharmaceutical/methods , Tissue Distribution
7.
Pharm Res ; 32(8): 2736-52, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25777611

ABSTRACT

PURPOSE: The synthesis and evaluation of novel biodegradable poly(organophosphazenes) (3-6) namely poly[bis-(2-propoxy)]phosphazene (3) poly[bis(4-acetamidophenoxy)]phosphazene (4)poly[bis(4-formylphenoxy)]phosphazene (5) poly[bis(4-ethoxycarbonylanilino)]phosphazene (6) bearing various hydrophilic and hydrophobic side groups for their application as nonocarrier system for antimalarial drug delivery is described. METHODS: The characterization of polymers was carried out by IR, (1)H-NMR and (31)P-NMR. The molecular weights of these novel polyphosphazenes were determined using size exclusion chromatography with a Waters 515 HPLC Pump and a Waters 2414 refractive index detector. The degradation behavior was studied by 200 mg pellets of polymers in phosphate buffers pH 5.5, 6.8 and 7.4 at 37°C. The degradation process was monitored by changes of mass as function of time and surface morphology of polymer pellets. The developed combined drugs nanoparticles formulations were evaluated for antimalarial potential in P. berghei infected mice. RESULTS: These polymers exhibited hydrolytic degradability, which can afford applications to a variety of drug delivery systems. On the basis of these results, the synthesized polymers were employed as nanocarriers for targeted drug delivery of primaquine and dihydroartemisinin. The promising in vitro release of both the drugs from nanoparticles formulations provided an alternative therapeutic combination therapy regimen for the treatment of drug resistant malaria. The nanoparticles formulations tested in resistant strain of P. berghei infected mice showed 100% antimalarial activity. CONCLUSIONS: The developed nanocarrier system provides an alternative combination regimen for the treatment of resistant malaria.


Subject(s)
Antimalarials/administration & dosage , Artemisinins/administration & dosage , Drug Carriers/chemical synthesis , Drug Carriers/pharmacology , Organophosphorus Compounds/chemical synthesis , Organophosphorus Compounds/pharmacology , Polymers/chemical synthesis , Polymers/pharmacology , Primaquine/administration & dosage , Animals , Antimalarials/chemistry , Artemisinins/chemistry , Drug Delivery Systems , Electrochemistry , Erythrocytes/drug effects , Humans , In Vitro Techniques , Malaria/drug therapy , Malaria/parasitology , Mice , Nanoparticles , Particle Size , Plasmodium berghei , Primaquine/chemistry , Spectrophotometry, Infrared , Survival Rate
8.
Indian J Pharm Sci ; 77(6): 705-14, 2015.
Article in English | MEDLINE | ID: mdl-26997698

ABSTRACT

Mucoadhesive tablets have emerged as potential candidates for gastroretentive drug delivery providing controlled release along with prolonged gastric residence time. Gastroretentive mucoadhesive tablets could result in increased bioavailability due to prolonged gastric residence time. A hydrophilic matrix system was developed as mucoadhesion is achievable on appropriate wetting and swelling of the polymers used. The polymers were so chosen so as to provide a balance between swelling, mucoadhesion and drug release. The polymers chosen were hydroxypropyl methylcellulose K4M, chitosan, and Carbopol 934. The concentrations of these polymers used has a great impact on the physicochemical properties of the resulting formulation. The tablets were formulated using wet granulation method and tranexamic acid was used as the model drug. The prepared tablets were characterized for size, shape, appearance, hardness, friability, weight variation, swelling, mucoadhesion and in vitro drug release. Several batches of tablets were prepared by varying the ratio of hydroxypropyl methylcellulose K4M and Chitosan. The batches having a greater ratio of chitosan showed higher rate of swelling, greater erosion, less mucoadhesion and faster release rate of the drug whereas the batches having greater ratio of hydroxypropyl methylcellulose K4M showed lesser rate of swelling, less erosion, better mucoadhesion and a smaller drug release rate. The level of carbopol was kept constant in all the batches.

9.
Eur J Pharm Sci ; 66: 123-37, 2015 Jan 23.
Article in English | MEDLINE | ID: mdl-25312346

ABSTRACT

Various polymer drug conjugates (13-16) such as primaquine and dihydroartemisinin conjugated 2-propoxy substituted polyphosphazenes (13), primaquine and dihydroartemisinin conjugated 4-acetamidophenoxy substituted polyphosphazenes (14), primaquine and dihydroartemisinin conjugated 4-formyl substituted polyphosphazenes (15) and primaquine and dihydroartemisinin conjugated 4-aminoethylbenzoate substituted polyphosphazenes (16) were synthesized using substituted polyphosphazenes as polymer and primaquine and dihydroartemisinin as combination antimalarial pharmacophores and formulated to nanoparticles to achieve novel controlled combined drug delivery approach for radical cure of malaria. The polymeric backbone was suitably substituted to impart different physicochemical properties. The polymer-drug conjugates were characterized by IR, (1)H NMR, (31)P NMR and their molecular weights were determined by Gel Permeation Chromatography. The thermal properties of the conjugates (13-16) were studied by DSC and TGA. The conjugates (13-16) were then formulated to nanoparticles formulations to increase their uptake by hepatocytes and to achieve targeted drug delivery. The nanoparticle formulations were characterized by Zeta Sizer and their morphology were studied by TEM (Transmission Electron Microscopy) imaging. The nanoparticles formulations exhibited biphasic in vitro drug release profile, the initial burst release followed by a sustained release owing to the non-fickian diffusion during first step release and fickian diffusion during second step release. In vivo antimalarial efficacy was tested using Plasmodium berghei (NK65 resistant strain) infected swiss albino mice at different doses. The combination therapy exhibited promising antimalarial efficacy at lower doses in comparison to the standard drug combination. Further, this combination therapy provided protection over 35days without any recrudescence, thus proving to be effective against resistant malaria. The study provides an alternative combination regimen found to be effective in the treatment of resistant malaria.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/chemistry , Artemisinins/therapeutic use , Organophosphorus Compounds/chemistry , Polymers/chemistry , Primaquine/chemistry , Primaquine/therapeutic use , Animals , Antimalarials/administration & dosage , Antimalarials/chemistry , Artemisinins/administration & dosage , Humans , Malaria/drug therapy , Malaria/parasitology , Mice , Molecular Structure , Nanoparticles , Plasmodium berghei , Primaquine/administration & dosage
10.
J Drug Target ; 23(1): 1-15, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25203856

ABSTRACT

Cancer becomes the leading cause of deaths worldwide, including breast cancer, prostate cancer and lung cancer that preferentially metastasize to bone and bone marrow. Bisphosphonates (BPs) have been used successfully for many years to reduce the skeletal complications related with the benign and malignant bone diseases that are characterized by enhanced osteoclastic bone resorption. Nitrogen-containing bisphosphonates (N-BPs) have also been demonstrated to exhibit direct anti-tumour effects. BPs binds avidly to the bone matrix, and released from matrix during bone resorption process, BPs are internalized by the osteoclasts where they interfere with biochemical pathways and induce osteoclast apoptosis. BPs also antagonizes the production of osteoclast and promotes the osteoblasts proliferation. Currently, Zoledronic acid is widely used as one of the BP having high bone specificity and potential to inhibit the osteoclast-mediated bone resorption. In addition to inhibition of cell multiplication and initiation of apoptosis in cultured cancer cells, they also interfere with adhesion of cancer cells to the bone matrix and inhibit cell migration and invasion. Pathophysiology and current target therapies like conjugate of BPs with liposomes, nanoparticle used for the treatment of bone cancer is reviewed in this article along with the use of different BPs.


Subject(s)
Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Diphosphonates/therapeutic use , Drug Delivery Systems/methods , Apoptosis/drug effects , Bone Resorption/drug therapy , Cell Movement/drug effects , Cell Proliferation/drug effects , Diphosphonates/pharmacology , Humans , Models, Biological , Molecular Targeted Therapy , Neoplasm Invasiveness , Osteoclasts/drug effects
11.
J Drug Target ; 22(10): 871-82, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25148607

ABSTRACT

Lymphatic system is a key target in research field due to its distinctive makeup and huge contributing functions within the body. Intestinal lymphatic drug transport (chylomicron pathway) is intensely described in research field till date because it is considered to be the best for improving oral drug delivery by avoiding first pass metabolism. The lymphatic imaging techniques and potential therapeutic candidates are engaged for evaluating disease states and overcoming these conditions. The novel drug delivery systems such as self-microemulsifying drug delivery system, nanoparticles, liposomes, nano-lipid carriers, solid lipid carriers are employed for delivering drugs through lymphatic system via various routes such as subcutaneous route, intraperitoneal route, pulmonary route, gastric sub-mucosal injection, intrapleural and intradermal. Among these colloidal particles, lipid-based delivery system is considered to be the best for lymphatic delivery. From the last few decades, mesenteric lymph duct cannulation and thoracic lymph duct cannulation are followed to assess lymphatic uptake of drugs. Due to their limitations, chylomicrons inhibitors and in-vitro models are employed, i.e. lipolysis model and permeability model. Currently, research on this topic still continues and drainage system used to deliver the drugs against lymphatic disease as well as targeting other organs by modulating the chylomicron pathway.


Subject(s)
Drug Delivery Systems , Lipids/chemistry , Lymphatic System/metabolism , Administration, Oral , Animals , Biological Transport , Chylomicrons/metabolism , Humans , Liposomes , Nanoparticles
12.
Drug Dev Ind Pharm ; 40(7): 869-78, 2014 Jul.
Article in English | MEDLINE | ID: mdl-23600649

ABSTRACT

Levodopa is the drug of choice in the treatment of Parkinson's disease but it exhibits low oral bioavailability (30%) and very low brain uptake due to its extensive metabolism by aromatic amino acid decarboxylase in the peripheral circulation. Hence, levodopa is co-administered with carbidopa, a peripheral amino acid decarboxylase inhibitor. In an attempt to improve brain uptake and to avoid degradation of levodopa in peripheral circulation and the use of carbidopa in combination, nose to brain drug delivery of levodopa alone via the olfactory route and the trigeminal nerves has been investigated. Chitosan nanoparticles loaded with levodopa (CNL) were prepared and were incorporated in a thermo-reversible gel prepared using Pluronic PF127 (CNLPgel). The preparation of CNL and CNLPgel was optimized for formulation parameters such as chitosan:TPP ratio, drug load Pluronic concentration to obtain desired particle size of CNL, gelling temperature, gelling time and mucoadhesive strength of CNLPgel. Rheological studies indicated a change in the rheological behavior of plain pluronic gel from Newtonian system at 30 °C to pseudoplastic behavior at 35 °C on incorporation of CNL. In vitro release studies from CNL obeyed Higuchi kinetic model, whereas the drug release from CNLPgel followed the Hixson-Crowell model. In vivo studies indicated a maximum recovery of the drug in brain following intranasal administration of CNL suspension in saline closely followed by the drug dispersed in plain pluronic gel.


Subject(s)
Antiparkinson Agents/administration & dosage , Brain/drug effects , Drug Carriers/chemistry , Levodopa/administration & dosage , Nanoparticles/chemistry , Nasal Mucosa/metabolism , Adhesiveness , Administration, Intranasal , Animals , Antiparkinson Agents/pharmacokinetics , Brain/metabolism , Chemistry, Pharmaceutical , Chitosan/chemistry , Drug Liberation , Gels , Levodopa/pharmacokinetics , Microscopy, Electron, Transmission , Particle Size , Poloxamer/chemistry , Rats, Wistar , Rheology , Temperature
13.
Adv Colloid Interface Sci ; 201-202: 1-17, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24192063

ABSTRACT

Malaria is an infectious disease that mainly affects children and pregnant women from tropical countries. The mortality rate of people infected with malaria per year is enormous and became a public health concern. The main factor that has contributed to the success of malaria proliferation is the increased number of drug resistant parasites. To counteract this trend, research has been done in nanotechnology and nanomedicine, for the development of new biocompatible systems capable of incorporating drugs, lowering the resistance progress, contributing for diagnosis, control and treatment of malaria by target delivery. In this review, we discussed the main problems associated with the spread of malaria and the most recent developments in nanomedicine for anti-malarial drug delivery.


Subject(s)
Antimalarials/administration & dosage , Colloids/chemistry , Drug Resistance, Multiple , Malaria/drug therapy , Nanomedicine/trends , Animals , Biocompatible Materials/chemistry , Child , Clinical Trials as Topic , Culicidae , Dendrimers/chemistry , Drug Delivery Systems , Drug Discovery , Female , Genetic Therapy , Humans , Lipids/chemistry , Liposomes/chemistry , Malaria Vaccines/therapeutic use , Male , Nanoparticles/chemistry , Plasmodium/metabolism , Polymers/chemistry , Pregnancy
14.
Curr Drug Deliv ; 2013 Nov 24.
Article in English | MEDLINE | ID: mdl-24266510

ABSTRACT

Hepatocellular carcinoma (HCC) is most common lethal malignancy worldwide. About 80% of liver cancer cases are attributed to the combined effects of Hepatitis B and C virus infections. The factors affecting development of HCC include cirrhosis and histological markers of increased liver cell proliferation, environmental, dietary and lifestyle of the person. Treatment options depend on the presence or absence of cirrhosis, number and size of tumors, and degree of hepatic deterioration. The primary option for some of the patients include hepatic resectioning, locoregional ablation, liver transplantation, ultrasound-guided tumor injection with absolute ethanol or tumor thermoablation with radiofrequency. Most common drugs like sorafenib, doxorubicin and daunorubicin have been used widely for treatment of HCC. A number of novel formulations like polymeric nanoparticles, nanocapsules, liposomes, nanoemulsions, microsphere, hydrogels, dendrimers, polymeric micelles has been reported for the treatment of HCC. The advantages of novel drug delivery systems (NDDS) is based on the ability to modify the bio-distribution, pharmacokinetics and pharmacological activity, prolonged efficacy and duration of drug activity, improved patient compliance, drug targeting to the site of action, enhancement of solubility, bioavailability, protection from toxicity, enhancement of stability. The carriers for liver specific drug delivery include liver-specific asialoglycoprotein receptor on mammalian hepatocytes. The natural ligand i.e. asialofeutin, or synthetic ligands with galactosylated or lactosylated polymers have been developed for significant targeting to the liver.

15.
Drug Deliv ; 20(5): 224-35, 2013.
Article in English | MEDLINE | ID: mdl-23651066

ABSTRACT

CONTEXT: Mucoadhesive buccal films containing three layers (mucoadhesive layer, nanosuspension containing layer and backing membrane) were incorporated with carvedilol nanosuspension. OBJECTIVE: Formulation and evaluation of nanosuspension incorporated mucoadhesive buccal films of carvedilol for bioavailability enhancement by avoiding first-pass metabolism. METHODS: Carvedilol-loaded nanosuspension was prepared by a precipitation-ultrasonication method with varying concentrations of the polymer. The formulation was analyzed for size, size distribution, surface charge and morphology. Optimized nanosuspension was incorporated into drug gel layer which was sandwiched between a mucoadhesive layer and a backing layer to form tri-layered buccal films. They were evaluated for their physical, mechanical and bioadhesive parameters followed by in vitro and in vivo studies. RESULTS AND DISCUSSION: Nanosuspension showed a negative zeta potential (-17.21 mV) with a diameter of around 495 nm and a polydispersity index of 0.203. Nanosuspension incorporated drug gel layer (62.4% drug loading) was optimized to contain 3% HPMC and 50 mg Carbopol 934P. The mucoadhesive layer and the backing layer were optimized to contain 3% HPMC and 1% ethyl cellulose, respectively. In vitro drug release was 69% and 62.4% in 9 h across synthetic membrane and porcine buccal mucosa, respectively. In vivo studies conducted in rabbit model showed 916% increase in the relative bioavailability in comparison to marketed oral tablet formulation. The C(max) and T(max) of the prepared formulation increased due to increased surface area of drug and also by-passing hepatic metabolism. CONCLUSION: The drug delivery system has been designed as a novel platform for potential buccal delivery of drugs having high first-pass metabolism.


Subject(s)
Antihypertensive Agents/chemistry , Carbazoles/chemistry , Drug Delivery Systems , Propanolamines/chemistry , Adhesiveness , Administration, Buccal , Animals , Carbazoles/administration & dosage , Carbazoles/metabolism , Carvedilol , Chemistry, Pharmaceutical , Particle Size , Permeability , Propanolamines/administration & dosage , Propanolamines/metabolism , Rabbits , Solubility , Suspensions , Swine
16.
Artif Cells Nanomed Biotechnol ; 41(1): 52-9, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22889361

ABSTRACT

Tuberculosis (TB) remains one of the oldest and deadliest diseases in the current scenario. The intracellular organism Mycobacterium tuberculosis, which mainly resides in mononuclear phagocytes, is responsible for tuberculosis in humans. A few therapies are available for the treatment of tuberculosis but they have many hurdles. To overcome these hurdles, a combination of chemotherapeutic agent-loaded vesicular systems have been prepared to overcome tuberculosis. To investigate the role of novel drug delivery systems for the treatment of pulmonary tuberculosis, ligand appended liposomals have been developed. In the present study, drug-loaded, ligand-appended liposomes and their DPI (Dry Powder Inhaler) forms have been prepared and characterized using various in vitro and in vivo parameters. The prepared ligand-appended liposomal formulation showed good entrapment efficiency, prolonged drug release, improved recovery of drugs from the target site, and proved to be more suitable for use as DPI, justifying their potential for improved drug delivery. Thus we tried our best by our project to reduce the national burden of tuberculosis, which is still a global health challenge.


Subject(s)
Drug Delivery Systems/methods , Liposomes/chemical synthesis , Mycobacterium tuberculosis/drug effects , Tuberculosis, Pulmonary/drug therapy , Animals , Antitubercular Agents/administration & dosage , Antitubercular Agents/chemical synthesis , Antitubercular Agents/pharmacokinetics , Drug Therapy, Combination , Humans , Isoniazid/administration & dosage , Isoniazid/chemical synthesis , Isoniazid/pharmacokinetics , Ligands , Pyrazinamide/administration & dosage , Pyrazinamide/chemical synthesis , Pyrazinamide/pharmacokinetics , Rats , Rats, Inbred Strains , Rifampin/administration & dosage , Rifampin/chemical synthesis , Rifampin/pharmacokinetics
17.
Cancer Nanotechnol ; 4(6): 145-157, 2013.
Article in English | MEDLINE | ID: mdl-26069510

ABSTRACT

The aim of the present study was the direct covalent coupling of the epidermal growth factor receptor (EGFR)-specific monoclonal antibody (mAb) to the surface of poly(lactide)-co-glycolide (PLGA)-polyethylene glycol (PEG) nanoparticles in order to achieve a cell type-specific drug carrier system against pancreatic cancer. The PLGA-PEG-NH2 diblock copolymer was synthesized by coupling reaction via amide linkage between PEG-diamine and activated PLGA. PLGA and PLGA-PEG-NH2 nanoparticles loaded with gemcitabine were prepared using the double-emulsion solvent evaporation method. PLGA-PEG immunonanoparticles were prepared by glutaraldehyde mediated cross-linking method. The conjugated antibody was analysed by transmission electron microscopy and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) analysis. Cell viability study was performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and cell uptake study was performed on fluorescein isothiocyanate-loaded formulations using confocal microscopy. The PAGE results indicated that mAb integrity was remained intact in the formulations after conjugation. Biological activity was confirmed under cell culture conditions: antibody-conjugated nanoparticles showed specific targeting to EGFR-overexpressing MIA PaCa-2 cell lines as shown in fluorescence image using confocal microscopy. The obtained data provide the basis for the development of stable and biologically active carrier systems for direct targeting of tumour cells using antibody-conjugated PLGA-PEG nanoparticles. Direct covalent coupling of antibodies to nanoparticles using glutaraldehyde as a cross-linker is an appropriate method to achieve cell type-specific drug carrier systems based on PLGA-PEG nanoparticles and the anti-EGFR-decorated PLGA-PEG nanoparticles have potentials to be applied for targeted chemotherapy against EGFR positive cancers.

18.
Drug Deliv ; 19(3): 155-67, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22364230

ABSTRACT

In the present study, six different molecular weight diblock copolymer of methoxy poly (ethylene glycol)-b-poly (ε-caprolactone) (MPEG-PCL) were synthesized and characterized and was used for fabrication of etoposide-loaded micelles by nanoprecipitation technique. The particle size and percentage drug entrapment of prepared micelles were found to be dependent on the molecular weight of PCL block and drug to polymer ratio. The maximum drug loading of 5.32% was found in micellar formulation MPEG5000-PCL10000, while MPEG2000-PCL2000 exhibited 2.73% of maximum drug loading. A variation in the fixed aqueous layer thickness and PEG surface density of micellar formulations was attributed to difference in MPEG molecular weight and interaction of PEG and PCL block of copolymer. The MPEG2000-PCL2000 micelles demonstrated poor in vitro stability among other micellar formulations, due to its interaction with bovine serum albumin and immediate release of drug from micelles. Furthermore, plain etoposide and MPEG2000-PCL2000 micelles exhibited greater extent of hemolysis, due to presence of surfactants and faster release of drug from micelles, respectively. The biodistribution studies carried out on Ehrlich ascites tumor-bearing Balb/C mice confirmed higher accumulation of etoposide-loaded micellar formulation at tumor site compared to plain etoposide due to enhanced permeability and retention effect.


Subject(s)
Drug Design , Ethylene Oxide/chemistry , Ethylene Oxide/metabolism , Etoposide/chemistry , Etoposide/metabolism , Lactones/chemistry , Lactones/metabolism , Micelles , Animals , Carcinoma, Ehrlich Tumor/drug therapy , Carcinoma, Ehrlich Tumor/metabolism , Drug Stability , Ethylene Oxide/administration & dosage , Etoposide/administration & dosage , Female , Lactones/administration & dosage , Mice , Mice, Inbred BALB C , Molecular Weight , Treatment Outcome , X-Ray Diffraction
19.
J Drug Target ; 20(1): 55-66, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21967151

ABSTRACT

BACKGROUND: Tumor-targeted delivery is a desirable approach to improve therapeutic outcome of anticancer drug due to enhanced efficacy and reduced toxicity. PURPOSE: The present study was aimed to target laminin receptor over-expressed tumor cells using YIGSR (Tyr-Ile-Gly-Ser-Arg) conjugated etoposide loaded micelles in the treatment of metastasis. METHODS: YIGSR conjugated micelles prepared using synthesized carboxyl and methoxy terminated poly(ethylene glycol)-b-poly(ϵ-caprolactone) block copolymers were evaluated for it efficacy against highly metastatic B16F10 cell lines conducting cytotoxicity, colony formation, cell migration, cellular uptake and flow cytometry studies. The in-vivo antimetastatic effect of micelles was evaluated using experimental metastatic model on C57BL/6 mice. RESULTS: YIGSR conjugated micelles of particle size 45.2±3.77 nm and zeta potential of-5.7±1.3 mV demonstrated enhanced cytotoxicity and cellular uptake with significant reduction in colony formation and cell migration activities compared to non-conjugated micelles. Furthermore, a markedly inhibition in lung colony formation was observed with these micelles. DISCUSSION: An enhanced cellular internalization of YIGSR conjugated micelles due to laminin receptor based endocytosis resulted in to higher cytotoxicity as well as antimetastatic effect against highly metastatic B16F10 cells. CONCLUSION: These studies indicate that YIGSR conjugated nanocarrier can be a promising approach in the treatment of tumor metastasis.


Subject(s)
Drug Delivery Systems/methods , Etoposide/administration & dosage , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Micelles , Polymers/administration & dosage , Receptors, Laminin , Animals , Etoposide/metabolism , Female , Lung Neoplasms/metabolism , Melanoma, Experimental/drug therapy , Melanoma, Experimental/metabolism , Melanoma, Experimental/secondary , Mice , Mice, Inbred C57BL , Polymers/metabolism , Random Allocation , Receptors, Laminin/metabolism , Treatment Outcome
20.
Cancer Nanotechnol ; 3(1-6): 25-36, 2012.
Article in English | MEDLINE | ID: mdl-26069494

ABSTRACT

PLGA nanoparticles, separately loaded with etoposide (ETN) and quercetin dihydrate (QDN), were prepared by adapting the solvent diffusion (nanoprecipitation) technique. The effect of formulation variables such as amount of polymer, theoretical drug loading, surfactant concentration, and aqueous and organic phase volumes on particle size and entrapment efficiency, were systematically studied. The optimal formulations obtained were of submicron size (153.4 ± 4.2 nm for ETN and 148.6 ± 1.6 nm for QDN) and with low polydispersity indices (0.058 ± 0.02 for ETN and 0.088 ± 0.03 for QDN). The entrapment efficiencies were found as 63.88 ± 1.5 % and 41.36 ± 3.4 % for ETN and QDN, respectively. The characterization of ETN and QDN was done by measuring the zeta potential, TEM, and DSC analysis. The comparison was made in respect of in vitro cytotoxicity assay using cancer cell line A549 (human lung adenocarcinoma epithelial cell line). The results revealed significant increase in cytotoxicity in nanoparticle formulations than their respective free drug. The comparison was also made with respect to cytotoxic activity of individual drug and combination of drugs in the form of free drugs as well as nanoparticles. The combination treatment in the form of nanoparticles is found to produce best results among the treatments used in cytotoxicity studies.

SELECTION OF CITATIONS
SEARCH DETAIL
...